Commentary on “A Vaccine for Photodynamic Immunogenic Cell Death: Tumor Cell Caged b y Cellular Disulfide–Thiol Exchange for Immunotherapy”

Tumor immunotherapy, including monoclonal antibody of immune checkpoint blockade, therapeutic antibody, cancer vaccine and cell therapy, etc., is to restart and maintain the tumor immune cycle, restore the normal antitumor immune response of the body, so as to control and eliminate the tumor [1,2]. Among them, tumor vaccine, which can elicit robust immune response and produce sustained immune memory effect, is particularly favored in the treatment and prevention of tumor recurrence [3,4]. Notably, compared with specific antigen vaccine, whole cell vaccine does not need complex antigen screening and purification process, and can provide all antigens of specific tumor, so it has great prospects [5,6]. Nevertheless, the immune effect of whole cell vaccine is not satisfactory because of its low immunogenicity and limitation efficiency of antigen presentation [7,8].